Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues
- PMID: 14587005
- DOI: 10.1002/mrm.10614
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues
Abstract
Proton high-resolution magic angle spinning ((1)H HR-MAS) NMR spectroscopy and quantitative histopathology were performed on the same 54 MRI/3D-MRSI-targeted postsurgical prostate tissue samples. Presurgical MRI/3D-MRSI targeted healthy and malignant prostate tissues with an accuracy of 81%. Even in the presence of substantial tissue heterogeneity, distinct (1)H HR-MAS spectral patterns were observed for different benign tissue types and prostate cancer. Specifically, healthy glandular tissue was discriminated from prostate cancer based on significantly higher levels of citrate (P = 0.04) and polyamines (P = 0.01), and lower (P = 0.02) levels of the choline-containing compounds choline, phosphocholine (PC), and glycerophosphocholine (GPC). Predominantly stromal tissue lacked both citrate and polyamines, but demonstrated significantly (P = 0.01) lower levels of choline compounds than cancer. In addition, taurine, myo-inositol, and scyllo-inositol were all higher in prostate cancer vs. healthy glandular and stromal tissues. Among cancer samples, larger increases in choline, and decreases in citrate and polyamines (P = 0.05) were observed with more aggressive cancers, and a MIB-1 labeling index correlated (r = 0.62, P = 0.01) with elevated choline. The elucidation of spectral patterns associated with mixtures of different prostate tissue types and cancer grades, and the inclusion of new metabolic markers for prostate cancer may significantly improve the clinical interpretation of in vivo prostate MRSI data.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.Magn Reson Med. 2006 Jun;55(6):1257-64. doi: 10.1002/mrm.20909. Magn Reson Med. 2006. PMID: 16685733
-
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.NMR Biomed. 2006 Feb;19(1):30-40. doi: 10.1002/nbm.992. NMR Biomed. 2006. PMID: 16229059 Clinical Trial.
-
Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.J Magn Reson Imaging. 2002 Oct;16(4):451-63. doi: 10.1002/jmri.10172. J Magn Reson Imaging. 2002. PMID: 12353259 Free PMC article. Review.
-
[Progress in nuclear magnetic resonance spectroscopy for early cancer diagnosis].Guang Pu Xue Yu Guang Pu Fen Xi. 2008 Aug;28(8):1942-50. Guang Pu Xue Yu Guang Pu Fen Xi. 2008. PMID: 18975839 Review. Chinese.
-
[1H magnetic resonance spectroscopy of the prostate].Radiologe. 2003 Jun;43(6):481-8. doi: 10.1007/s00117-003-0902-y. Radiologe. 2003. PMID: 12827263 Review. German.
Cited by
-
Developments in proton MR spectroscopic imaging of prostate cancer.MAGMA. 2022 Aug;35(4):645-665. doi: 10.1007/s10334-022-01011-9. Epub 2022 Apr 20. MAGMA. 2022. PMID: 35445307 Free PMC article. Review.
-
Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR.Front Aging Neurosci. 2019 Jan 9;10:424. doi: 10.3389/fnagi.2018.00424. eCollection 2018. Front Aging Neurosci. 2019. PMID: 30687076 Free PMC article.
-
Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):853-859. doi: 10.1093/gerona/gly128. J Gerontol A Biol Sci Med Sci. 2019. PMID: 29878065 Free PMC article.
-
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175. PLoS One. 2010. PMID: 21151972 Free PMC article.
-
A decade in prostate cancer: from NMR to metabolomics.Nat Rev Urol. 2011 May 17;8(6):301-11. doi: 10.1038/nrurol.2011.53. Nat Rev Urol. 2011. PMID: 21587223 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources